Sang 2004.

Methods	Multicentre, randomised, triple‐blind, placebo‐controlled, parallel‐group. Single dose to treat single attack. Medication administered when migraine headache pain was of moderate or severe intensity Assessments at 15, 30, 45, 60, and 90 mins and 2, 3, 4, and 24 h after dosing Rescue medication (excluding ergot derivatives) was available at the participant's request after 2 h
Participants	Aged 18 years or older, meeting IHS criteria for migraine (1988) with or without aura. At least 1‐year history of migraine (untreated severity ≥ moderate) with an average of 1 to 15 attacks per month. N = 44 M 20, F 24 (55%) Mean age 40 years Without aura 89%
Interventions	Sumatriptan 6 mg, n = 15 Intravenous LY293558 1.2 mg/kg, n = 13 Placebo, n = 16 (15 with moderate or severe baseline pain intensity)
Outcomes	Headache relief (at 1 and 2 h) Pain‐free (at 1 and 2 h) Use of rescue medication Adverse events
Notes	Oxford Quality Score: R1, DB2, W1. Total = 4.
Risk of bias
Bias	Authors' judgement	Support for judgement
Random sequence generation (selection bias)	Unclear risk	Not reported
Allocation concealment (selection bias)	Low risk	Allocation balanced between treatments with a block size equal to 3; randomisation code kept under lock and only accessed by pharmacist or designee
Blinding (performance bias and detection bias) All outcomes	Low risk	Double‐dummy
Study size	High risk	Treatment groups < 50 participants